119 related articles for article (PubMed ID: 1703919)
1. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Moritz TE; Rousseau SM; Stump DC
Cancer; 1991 Mar; 67(5):1377-83. PubMed ID: 1703919
[TBL] [Abstract][Full Text] [Related]
2. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Cancer; 1990 Feb; 65(3):481-5. PubMed ID: 2153429
[TBL] [Abstract][Full Text] [Related]
3. Indirect activation of blood coagulation in colon cancer.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Thromb Haemost; 1989 Dec; 62(4):1062-6. PubMed ID: 2694422
[TBL] [Abstract][Full Text] [Related]
4. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Am J Clin Pathol; 1990 Apr; 93(4):516-21. PubMed ID: 1690950
[TBL] [Abstract][Full Text] [Related]
5. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Ornstein DL; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Hunt J; Rousseau SM; Stump DC
Cancer; 1991 Sep; 68(5):1061-7. PubMed ID: 1913476
[TBL] [Abstract][Full Text] [Related]
6. Localization of blood coagulation factors in situ in pancreatic carcinoma.
Wojtukiewicz MZ; Rucinska M; Zacharski LR; Kozlowski L; Zimnoch L; Piotrowski Z; Kudryk BJ; Kisiel W
Thromb Haemost; 2001 Dec; 86(6):1416-20. PubMed ID: 11776308
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Camiolo SM; Markus G; Englander LS; Siuta MR; Hobika GH; Kohga S
Cancer Res; 1984 Jan; 44(1):311-8. PubMed ID: 6197164
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Anticancer Res; 1990; 10(3):579-82. PubMed ID: 2114816
[TBL] [Abstract][Full Text] [Related]
9. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.
Wojtukiewicz MZ; Sierko E; Zacharski LR; Zimnoch L; Kudryk B; Kisiel W
Semin Thromb Hemost; 2003 Jun; 29(3):291-300. PubMed ID: 12888933
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Zacharski LR; Memoli VA; Ornstein DL; Rousseau SM; Kisiel W; Kudryk BJ
J Natl Cancer Inst; 1993 Aug; 85(15):1225-30. PubMed ID: 8331683
[TBL] [Abstract][Full Text] [Related]
11. Pathways of coagulation activation in situ in rheumatoid synovial tissue.
Zacharski LR; Brown FE; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Hunt JA; Dunwiddie C; Nutt EM
Clin Immunol Immunopathol; 1992 May; 63(2):155-62. PubMed ID: 1611717
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity.
Camiolo SM; Markus G; Evers JL; Hobika GH; DePasquale JL; Beckley S; Grimaldi JP
Int J Cancer; 1981 Feb; 27(2):191-8. PubMed ID: 6169657
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue.
Kirchheimer J; Köller A; Binder BR
Biochim Biophys Acta; 1984 Feb; 797(2):256-65. PubMed ID: 6199043
[TBL] [Abstract][Full Text] [Related]
14. [Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer].
Pflüger H; Kirchheimer J; Ritschl P; Köller A; Hienert G; Binder BR
Wien Klin Wochenschr; 1984 Sep; 96(17):658-61. PubMed ID: 6083673
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC
Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen deposition and macrophage-associated fibrin formation in malignant and nonmalignant lymphoid tissue.
Costantini V; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
J Lab Clin Med; 1992 Feb; 119(2):124-31. PubMed ID: 1740624
[TBL] [Abstract][Full Text] [Related]
17. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
Gram J
Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator activity in prostatic cancer.
Köller A; Kirchheimer J; Pflüger H; Binder BR
Eur Urol; 1984; 10(6):389-94. PubMed ID: 6085049
[TBL] [Abstract][Full Text] [Related]
20. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
Cassels R; Fears R; Smith RA
Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
